MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: KDM Communications Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pro-Lab Diagnostics Launches Prolisa™ Cryptosporidium/Giardia Enzyme Immunoassay - Pro-Lab Diagnostics has developed a new enzyme immunoassay (EIA) for the qualitative detection of Cryptosporidium and Giardia lamblia antigens in human faecal specimens from patients displaying gastrointestinal symptoms - Pro-Lab.com
Pro-Lab Diagnostics Launches Prolisa™ Cryptosporidium/Giardia Enzyme Immunoassay

 

NewswireToday - /newswire/ - St Neots, Cambridgeshire, United Kingdom, 2012/02/24 - Pro-Lab Diagnostics has developed a new enzyme immunoassay (EIA) for the qualitative detection of Cryptosporidium and Giardia lamblia antigens in human faecal specimens from patients displaying gastrointestinal symptoms - Pro-Lab.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Prolisa™ Cryptosporidium/Giardia EIA kit offers precise results with high sensitivity and excellent specificity, enabling accurate diagnosis of infection.

Cryptosporidiosis is routinely diagnosed by microscopic analysis of stool samples using organic dyes or by immunostaining by direct fluorescent antibody, and can be difficult to detect. Similarly, Giardia infection is frequently misdiagnosed, relying on poorly performing antigen-based testing. Pro-Lab Diagnostics’ Prolisa™ Cryptosporidium/Giardia EIA is a convenient, rapid and easy-to-use method of detecting Cryptosporidium and G. lamblia. Supplied in a 96-well test size consisting of detachable stripwells, this manual assay uses monoclonal anti-Cryptosporidium and anti- G. lamblia antibodies to ensure excellent sensitivity and specificity for high value diagnostic results, and can also be performed on most automated platforms for increased workflow flexibility. Mark Reed, General Manager of Pro-Lab Diagnostics, commented: “The launch of the Cryptosporidium/Giardia EIA further extends the Prolisa product range, offering our customers a simple and cost-effective alternative means of testing for Cryptosporidiosis and Giardiasis with the back-up support of our team of application experts.”

About Pro-Lab Diagnostics

The Pro-Lab Group of companies (pro-lab.com) is dedicated to the provision of high quality, cost effective immunodiagnostic products and biological reagents to hospitals, private medical laboratories, veterinary laboratories, and other biological investigative laboratories. Pro-Lab Diagnostics is a privately held corporation founded in 1974 with its head office in Toronto, Canada and subsidiaries in the U.K. and U.S.A.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: KDM Communications Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pro-Lab Diagnostics Launches Prolisa™ Cryptosporidium/Giardia Enzyme Immunoassay

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sophie Woodward - KDM-Communications.com 
+44(0)15 1353 1613 uksupport[.]pro-lab.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any KDM Communications Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From KDM Communications Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)